Compare REPL & TLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REPL | TLS |
|---|---|---|
| Founded | 2015 | 1969 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 454.6M | 365.1M |
| IPO Year | 2018 | 2020 |
| Metric | REPL | TLS |
|---|---|---|
| Price | $12.21 | $4.58 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 5 |
| Target Price | $5.67 | ★ $7.90 |
| AVG Volume (30 Days) | ★ 6.3M | 401.5K |
| Earning Date | 05-21-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.51 |
| EPS | N/A | ★ 0.03 |
| Revenue | N/A | ★ $164,805,000.00 |
| Revenue This Year | N/A | $18.72 |
| Revenue Next Year | N/A | $14.62 |
| P/E Ratio | ★ N/A | $156.00 |
| Revenue Growth | N/A | ★ 52.21 |
| 52 Week Low | $1.50 | $2.37 |
| 52 Week High | $13.86 | $8.36 |
| Indicator | REPL | TLS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.
Telos Corp offers technology solutions and services that empower and protect the world's security-conscious organizations. The company delivers efficient, adaptable, and secure solutions that protect people, organizations, and information across government and industry. The company conducts its business through two reportable and operating segments: Security Solutions and Secure Networks. The Security Solutions segment is focused on cybersecurity, cloud, and identity solutions, and secure messaging through Xacta, Telos AMHS, and Telos ID offerings. The Secure Networks segment provides secure networking architectures and solutions to customers through secure mobility solutions, network management, and defense services. The majority of revenue is from Secure Networks.